Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial.
Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, LaRosa S, Wittebole X, Dhainaut JF, Doig C, Mendelson MH, Zwingelstein C, Su G, Opal S; CAPTIVATE Trial Group. Wunderink RG, et al. Among authors: wittebole x. Am J Respir Crit Care Med. 2011 Jun 1;183(11):1561-8. doi: 10.1164/rccm.201007-1167OC. Epub 2011 Feb 4. Am J Respir Crit Care Med. 2011. PMID: 21297074 Clinical Trial.
Epidemiology, Outcomes, and Complement Gene Variants in Secondary Thrombotic Microangiopathies.
Werion A, Storms P, Zizi Y, Beguin C, Bernards J, Cambier JF, Dahan K, Dierickx D, Godefroid N, Hilbert P, Lambert C, Levtchenko E, Meyskens T, Poiré X, van den Heuvel L, Claes KJ, Morelle J; UCLouvain TMA/HUS Network and KU Leuven TMA/HUS Network. Werion A, et al. Clin J Am Soc Nephrol. 2023 Apr 21;18(7):881-91. doi: 10.2215/CJN.0000000000000182. Online ahead of print. Clin J Am Soc Nephrol. 2023. PMID: 37094330
Anticoagulant therapy in acute lung injury.
Laterre PF, Wittebole X, Dhainaut JF. Laterre PF, et al. Among authors: wittebole x. Crit Care Med. 2003 Apr;31(4 Suppl):S329-36. doi: 10.1097/01.CCM.0000057912.71499.A5. Crit Care Med. 2003. PMID: 12682461 Review.
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente JA, McGee W, Reinhart K, Kljucar S, Souza S, Pribble J; Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators. Opal S, et al. Among authors: wittebole x. Crit Care Med. 2004 Feb;32(2):332-41. doi: 10.1097/01.CCM.0000108867.87890.6D. Crit Care Med. 2004. PMID: 14758145 Clinical Trial.
Pharmacological inhibition of tissue factor.
Laterre PF, Wittebole X, Collienne C. Laterre PF, et al. Among authors: wittebole x. Semin Thromb Hemost. 2006 Feb;32(1):71-6. doi: 10.1055/s-2006-933342. Semin Thromb Hemost. 2006. PMID: 16479464 Review.
Systemic and local high mobility group box 1 concentrations during severe infection.
van Zoelen MA, Laterre PF, van Veen SQ, van Till JW, Wittebole X, Bresser P, Tanck MW, Dugernier T, Ishizaka A, Boermeester MA, van der Poll T. van Zoelen MA, et al. Among authors: wittebole x. Crit Care Med. 2007 Dec;35(12):2799-804. doi: 10.1097/01.CCM.0000287588.69000.97. Crit Care Med. 2007. PMID: 17901841
149 results